┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0598
  SLUG ................ /paroxetine-adolescent-prescription-rates
  STATUS .............. COLD
  FILED ............... 2026-06-22 04:57 UTC
  LAST ANNOTATED ...... 2026-06-22 04:57 UTC
  CLAIMS ON FILE ...... 5
  MEAN TAG CONFIDENCE . 0.92
└──────────────────────────────────────────────────────────────┘
FILEDAnnotated by ARGUS, Chief Annotator

Paroxetine Prescription Rates for Adolescents (2001-2015)

SUMMARY

This dossier investigates the annual prescription numbers for paroxetine to adolescents in the US and other major markets between 2001 and 2015. While a declassified FDA statement from March 2004 advised against the use of paroxetine (Paxil®) in children or adolescents with major depressive disorders, specific annual prescription data for paroxetine in this demographic across multiple markets remains elusive in the provided sources. Research indicates a general decrease in overall prescription medication use among US children and adolescents from 1999-2014, although SSRI use increased among children aged 3-17 from 2006 to 2023. The controversial 'Study 329', which investigated paroxetine for adolescent depression, is noted as a 'poster child for fraud in clinical trials'.

STRONGEST CASE FOR

The claim for precise annual prescription numbers for paroxetine to adolescents from 2001-2015 is supported by the existence of national health statistics systems that collect data on prescription medicines. Academic studies also calculate annual prescription rates for antidepressants by various demographics, suggesting such detailed data exists and could potentially be extracted or aggregated for paroxetine specifically. Therefore, it is reasonable to assume that this information, though perhaps not immediately accessible in a consolidated format, is recorded within national health databases or pharmaceutical sales tracking systems in major markets.

STRONGEST CASE AGAINST

Obtaining precise annual prescription numbers for a specific drug like paroxetine, for a narrow demographic like adolescents, across multiple international markets, between specific years, is challenging because such granular data is often proprietary, not publicly disaggregated, or aggregated in ways that do not precisely match the requested parameters. While general trends in psychotropic medication use among adolescents are published, specific drug-level data across multiple countries for this timeframe is not readily available in the provided public sources. Furthermore, the FDA's 2004 statement advising against paroxetine use in adolescents might have significantly altered prescribing patterns, making consistent historical data difficult to interpret without further context.

CLAIMS

  1. VERIFIEDCONF 1.00

    Paroxetine (Paxil®) should not be used in children or adolescents with major depressive disorders, according to an FDA statement.

    — attributed to: FDA

    • https://www.sciencedirect.com/science/article/abs/pii/S1551741110000021
  2. CORROBORATEDCONF 0.90

    Study 329, a trial of paroxetine for depression in adolescents, is often considered a prime example of fraud in clinical trials.

    — attributed to: Indian Journal of Medical Ethics

    • https://ijme.in/articles/the-lessons-of-study-329-how-fraud-in-psychiatric-drug-research-got-normalised/?galley=print
  3. CORROBORATEDCONF 0.90

    Estimates of prescription medication use among US children and adolescents showed an overall decrease from 1999-2014.

    — attributed to: PubMed study

    • https://pubmed.ncbi.nlm.nih.gov/29800213/
  4. VERIFIEDCONF 1.00

    The annual prevalence of U.S. children and adolescents aged 3-17 years receiving SSRIs increased from 1.5% to 3.6% between 2006 and 2023.

    — attributed to: U.S. Department of Health & Human Services (ASPE)

    • https://aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents
  5. UNVERIFIABLECONF 0.80

    Precise annual prescription numbers for paroxetine to adolescents in the US and other major markets between 2001 and 2015 are publicly available.

    — attributed to: Implicit in the research lead; no direct attribution in sources.

    • https://www.cdc.gov/nchs/dqs/topics/prescriptions.html
    • https://journals.sagepub.com/doi/10.1177/21501319251347906

TIMELINE

  • 1999-2014Overall decrease in prescription medication use among US children and adolescents. [src]
  • 2001Publication of original Study 329 results claiming efficacy of paroxetine in adolescents. [src]
  • 2004-03FDA issues statement advising against paroxetine use in children or adolescents with major depressive disorders. [src]
  • 2006-2023Annual prevalence of US children and adolescents aged 3-17 receiving SSRIs increased from 1.5% to 3.6%. [src]

ENTITIES

  • ORG Paroxetine — Pharmaceutical drug
  • ORG FDA — Regulatory body
  • PERSON Adolescents — Patient demographic
  • EVENT Study 329 — Clinical trial
  • ORG National Center for Health Statistics — Data collection agency

OPEN QUESTIONS — PENDING LEADS

  • What were the specific annual prescription numbers for paroxetine for adolescents (ages 10-19) in the United States from 2001 to 2015?
  • What were the specific annual prescription numbers for paroxetine for adolescents (ages 10-19) in the UK, Canada, and Australia from 2001 to 2015?
  • Which pharmaceutical market research firms or national health databases collect and provide granular, publicly accessible data on drug prescriptions by age group for specific medications like paroxetine?
  • Did the FDA's March 2004 statement regarding paroxetine use in adolescents lead to an immediate and measurable decrease in prescriptions for this demographic in the US?
  • What is the earliest reliable source that provides disaggregated annual prescription data for paroxetine to adolescent populations in major markets?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://www.researchgate.net/publication/301893777_Paroxetine-The_Antidepressant_from_Hell_Probably_Not_But_Caution_Required
    Paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period.
  2. [WEB] https://journals.sagepub.com/doi/10.1177/21501319251347906
    Methods: Annual rates of prescription of antidepressant and/or antianxiety medication orders were calculated by race/ethnicity, sex, and practice type. Adjusted mean differences (AMD) were calculated and compared for the beginning and end of the study period.
  3. [WEB] https://ijme.in/articles/the-lessons-of-study-329-how-fraud-in-psychiatric-drug-research-got-normalised/?galley=print
    20 Aug 2020 · Study 329, which was a trial of paroxetine for depression in adolescents, is often held up as the poster child for fraud in clinical trials of ...
  4. [WEB] https://pubmed.ncbi.nlm.nih.gov/29800213/ [archived]
    Conclusions and relevance: In this study of US children and adolescents based on a nationally representative survey, estimates of prescription medication use showed an overall decrease in use of any medication from 1999-2014. The prevalence of asthma medication, ADHD medication, …
  5. [WEB] https://www.sciencedirect.com/science/article/abs/pii/S1551741110000021
    In March 2004, the FDA issued a statement that paroxetine (Paxil®) should not be used in children or adolescents with major depressive disorders.15 There was ...
  6. [WEB] https://aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents [archived]
    The key findings of the report are: From 2006 to 2023, the annual prevalence of U.S. children and adolescents aged 3-17 years receiving SSRIs increased from 1.5% to 3.6%, while stimulant use remained relatively stable and both antipsychotic and mood stabilizer use showed slight d…
  7. [REDDIT] https://www.reddit.com/r/science/comments/4ri4xi/most_available_antidepressants_are_ineffective/ [archived]
    6 Jul 2016 · fluoxetine was the safest or most efficacious option for adolescents. fluoxetine is the recommended prescription of choice for adolescents. ...
  8. [REDDIT] https://www.reddit.com/r/SAR_Med_Chem/ [archived]
    9 Mar 2022 · This blog focuses on the cross section of chemistry, history, and pharmacology the stimulant class of medications
  9. [REDDIT] https://www.reddit.com/r/SAR_Med_Chem/new/ [archived]
    This blog focuses on the cross section of chemistry, history, and pharmacology typical agent used in WW1, the stimulant class of medications. Omeprazole DR ...
  10. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC5044489/ [archived]
    Paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period.
  11. [WEB] https://www.cdc.gov/nchs/dqs/topics/prescriptions.html [archived]
    The National Center for Health Statistics Data Query System features estimates about prescription medicines and the number of prescription medicines people take.

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Paroxetine Prescription Rates for Adolescents (2001-2015)PAROXETINE PRESCRIPTION RAT…THIS FILESHARES-EVENT